Oncotelic Therapeutics Files 8-K

TL;DR

Oncotelic filed an 8-K on Dec 31, 2024, mostly for financial docs.

AI Summary

Oncotelic Therapeutics, Inc. filed an 8-K on January 2, 2025, reporting events as of December 31, 2024. The filing primarily concerns financial statements and exhibits, with no specific material events detailed in the provided text.

Why It Matters

This 8-K filing indicates the company is providing updated financial information and exhibits to the SEC, which is standard practice for public companies.

Risk Assessment

Risk Level: low — The filing appears to be routine and does not disclose any new material adverse events or significant financial changes.

Key Players & Entities

• Oncotelic Therapeutics, Inc. (company) — Registrant
• December 31, 2024 (date) — Date of earliest event reported
• January 2, 2025 (date) — Filing date
• Delaware (jurisdiction) — State of incorporation
• 29397 Agoura Road, Suite 107 (address) — Principal executive offices
• Agoura Hills, CA 91301 (address) — Principal executive offices
• (650) 635-7000 (phone_number) — Registrant's telephone number

FAQ

Filing Documents

• form8-k.htm (8-K) — 41KB
• ex10-1.htm (EX-10.1) — 16KB
• ex10-1_001.jpg (GRAPHIC) — 25KB
• ex10-1_002.jpg (GRAPHIC) — 1KB
• 0001493152-25-000028.txt ( ) — 262KB
• otlc-20241231.xsd (EX-101.SCH) — 3KB
• otlc-20241231_lab.xml (EX-101.LAB) — 33KB
• otlc-20241231_pre.xml (EX-101.PRE) — 24KB
• form8-k_htm.xml (XML) — 3KB

From the Filing

UNITED SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) December 31, 2024 ONCOTELIC THERAPEUTICS, INC. (Exact name of registrant as specified in its charter) Delaware 000-21990 13-3679168 (State or other jurisdiction of incorporation) (Commission File Number) (IRS Employer Identification No.) 29397 Agoura Road , Suite 107 Agoura Hills , CA 91301 (Address of principal executive offices and Zip Code) Registrant's telephone number, including area code (650) 635-7000 Not applicable. (Former name or former address, if changed since last report.) Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions ( see General Instruction A.2. below): Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) Securities registered pursuant to Section 12(b) of the Act: Title of class Trading Symbols Name of each exchange on which registered N/A OTLC Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (240.12b-2 of this chapter). Emerging growth company If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. Item 8.01 Other Events. On April 29, 2024, Oncotelic Therapeutics, Inc. (the " Company ") reported on a Current Report on Form 8-K, that the Company had entered into a binding term sheet with Mosaic ImmunoEngineering, Inc. (" Mosaic ") on April 26, 2024. Amongst other items, the term sheet was set to expire 90 days from the date of the term sheet and contained a term for the possible reverse merger of Mosaic with Oncotelic under certain circumstances (the " Proposed Transaction" ). A copy of the binding term sheet was included as Exhibit 10.1 to the Current Report on Form 8-K mentioned above. Subsequently, the Company reported, as a subsequent event, on its Quarterly Report on Form 10-Q for the three and six months ended June 30, 2024 filed with the Securities and Exchange Commission (" SEC" ) on August 14, 2024, the extension of the term contained in the binding term sheet to December 31, 2024 to complete the Proposed Transaction. On December 31, 2024, the Company and Mosaic decided to pursue the Proposed Transaction, in the best interests of both companies, and mutually agreed to further extend the date of the Proposed Transaction to no later than June 30, 2025: although there are no guarantees we will enter into any definitive agreement. A copy of the term extension letter is filed herewith as Exhibit 10.1 to this Current Report on Form 8-K. Disclaimer. The information in Section 8.01 of this Current Report on Form 8-K, including the information set forth in Exhibit 10.1, is being furnished and shall not be deemed "filed" for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the " Exchange Act "), nor be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as shall be expressly set forth by specific reference in such a filing. Item 9.01 Financial Statements and Exhibits. (d) Exhibits. Exhibit No. Description Filed on 10.1 Term Extension Letter dated December 31, 2024 Filed herewith 104 Cover Page Interactive Data File (embedded within the Inline XBRL document) SIGNATURE Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. Oncotelic Therapeutics, Inc. Date: January 2, 2025 By: /s/ Vuong Trieu Vuong Trieu Chief Executive Officer

View Full Filing

View this 8-K filing on SEC EDGAR